191 related articles for article (PubMed ID: 7120130)
1. Cardiovascular pharmacology of ASL-7022, a novel catecholamine. I. Inotropic, chronotropic and pressor actions.
Gorczynski RJ
J Pharmacol Exp Ther; 1982 Oct; 223(1):7-11. PubMed ID: 7120130
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular pharmacology of ASL-7022. II. Mechanisms of inotropic selectivity.
Gorczynski RJ; Wroble RW
J Pharmacol Exp Ther; 1982 Oct; 223(1):12-9. PubMed ID: 6126579
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular pharmacology of ASL-7022. III. Peripheral vascular adrenergic mechanisms.
Gorczynski RJ; Reynolds RD
J Pharmacol Exp Ther; 1985 Mar; 232(3):629-35. PubMed ID: 2857783
[TBL] [Abstract][Full Text] [Related]
4. Integrative cardiovascular actions of a novel catecholamine, GP-2-128.
Abou-Mohamed G; Caldwell RW; Ibrahim TM; Tuttle RR
J Cardiovasc Pharmacol; 1994 Mar; 23(3):485-91. PubMed ID: 7515995
[TBL] [Abstract][Full Text] [Related]
5. Chronotropic and inotropic responses to ASL-7022 on isolated rat atria.
Gende OA; Camilión de Hurtado MC
Acta Physiol Pharmacol Latinoam; 1989; 39(2):119-26. PubMed ID: 2618750
[TBL] [Abstract][Full Text] [Related]
6. The inotropic actions of N-acetylprocainamide: blockade and reversal by propranolol.
Lertora JJ; King LW; Donkor KA
Angiology; 1986 Dec; 37(12 Pt 2):939-49. PubMed ID: 2433968
[TBL] [Abstract][Full Text] [Related]
7. [General pharmacological actions of traxanox sodium. II. Effects on the cardiovascular system].
Nakamura T; Miura Y; Aihara K; Satoh H; Goto K; Tsumagari T
Nihon Yakurigaku Zasshi; 1983 Jul; 82(1):79-92. PubMed ID: 6137441
[TBL] [Abstract][Full Text] [Related]
8. Systemic, pulmonary and coronary haemodynamic actions of the novel dopamine receptor agonist in awake pigs at rest and during treadmill exercise Z1046.
Duncker DJ; Haitsma DB; van der Geest IE; Stubenitsky R; van Meegen JR; Man in't Veld AJ; Verdouw PD
Br J Pharmacol; 1997 Mar; 120(6):1101-13. PubMed ID: 9134223
[TBL] [Abstract][Full Text] [Related]
9. Beta-blocking and hemodynamic effects of ASL-8052.
Gorczynski RJ; Murthy VS; Hwang TF
J Cardiovasc Pharmacol; 1984; 6(6):1548-59. PubMed ID: 6084788
[TBL] [Abstract][Full Text] [Related]
10. Interaction of the novel inotropic agent, ASL-7022, with alpha and beta adrenoceptors in the cardiovascular system of the pithed rat: comparison with dobutamine and dopamine.
Ruffolo RR; Morgan EL
J Pharmacol Exp Ther; 1984 May; 229(2):364-71. PubMed ID: 6325661
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular properties of a new cardiotonic agent: MDL 17,043 (1.3-dihydro-4-methyl-5-[4-(methylthio)-benzoyl]-2H-imidazol-2-one).
Dage RC; Roebel LE; Hsieh CP; Weiner DL; Woodward JK
J Cardiovasc Pharmacol; 1982; 4(3):500-8. PubMed ID: 6177949
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo studies of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone (OPC-8212), a novel positive inotropic drug, in various animals.
Yamashita S; Hosokawa T; Kojima M; Mori T; Yabuuchi Y
Arzneimittelforschung; 1984; 34(3A):342-6. PubMed ID: 6331464
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms mediating the positive inotropic and chronotropic changes induced by dopexamine in the anesthetized dog.
Bass AS; Kohli JD; Lubbers N; Goldberg LI
J Pharmacol Exp Ther; 1987 Sep; 242(3):940-4. PubMed ID: 2888876
[TBL] [Abstract][Full Text] [Related]
14. The cardiovascular actions of dopamine and the effects of central and peripheral catecholaminergic receptor blocking drugs.
Setler PE; Pendleton RG; Finlay E
J Pharmacol Exp Ther; 1975 Mar; 192(3):702-12. PubMed ID: 1120964
[TBL] [Abstract][Full Text] [Related]
15. Possible involvement of indirect mechanism in cardiovascular action of dobutamine in dogs.
Morishita H; Furukawa T
Arch Int Pharmacodyn Ther; 1979 May; 239(1):121-7. PubMed ID: 485708
[TBL] [Abstract][Full Text] [Related]
16. Cardiac effects of the novel pyridazinone derivative 6-[4-[2-[3-(5-chloro-2-cyanophenoxy)-2-hydroxypropylamino]- 2- methylpropylamino]phenyl]-4,5-dihydro-5-methyl-3(2H) pyridazinone monoethyl maleate and its metabolite in isolated heart preparations of guinea pigs and dogs.
Ishimori T; Gotanda K; Sasaki T; Shinbo A; Asano H; Miyazawa K; Miyasaka K
Arzneimittelforschung; 1994 May; 44(5):583-8. PubMed ID: 7912931
[TBL] [Abstract][Full Text] [Related]
17. Insulin infusion in conscious dogs. Effects on systemic and coronary hemodynamics, regional blood flows, and plasma catecholamines.
Liang C; Doherty JU; Faillace R; Maekawa K; Arnold S; Gavras H; Hood WB
J Clin Invest; 1982 Jun; 69(6):1321-36. PubMed ID: 6123523
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular effects of (2RS,3SR)- 2-aminomethyl-2,3,7,8-tetrahydro-2,3,5,8,8-pentamethyl-6H-furo- [2,3-e]indol-7-one hydrochloride (UK-1745), a novel cardiotonic agent with vasodilatory and antiarrhythmic properties.
Uchida Y; Kawada M; Sawanobori K; Sonoki H; Inoue K; Mizuno K; Itou T; Tabunoki Y; Tsukamoto M; Ohashi Y; Kyotani Y; Shimizu N; Fujii M; Nakamura M
Arzneimittelforschung; 1998 Mar; 48(3):219-31. PubMed ID: 9553677
[TBL] [Abstract][Full Text] [Related]
19. C-type natriuretic peptide increases myocardial contractility and sinus rate mediated by guanylyl cyclase-linked natriuretic peptide receptors in isolated, blood-perfused dog heart preparations.
Hirose M; Furukawa Y; Kurogouchi F; Nakajima K; Miyashita Y; Chiba S
J Pharmacol Exp Ther; 1998 Jul; 286(1):70-6. PubMed ID: 9655843
[TBL] [Abstract][Full Text] [Related]
20. Positive inotropic effect of 3, 4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-qu inolinone (OPC-8212) in the dog with experimentally-induced right-sided heart failure.
Hashimoto K; Yabuuchi Y; Yamashita S; Mori T
Arzneimittelforschung; 1984; 34(3A):390-3. PubMed ID: 6540094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
